Henter ID

Experimental Therapeutics and Pathophysiology Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, United States.

9 papers · ORCID

ArticlePsilocybin

Effects of psychedelic drug use on neurocognitive function and the psychological and social domains of quality of life: an international online study.

Stadler F, Saelens J, Henter ID +6

Europe PMC2026
ArticleKetamine

Convergent neuroimmune signaling underlying rapid antidepressant response to ketamine and psychedelics.

Jones GH, Gilbert JR, Johnston JN +20

Europe PMC2026
ArticlePsilocybin

Time-dependent effects of rapid-acting antidepressants in iPSC-derived neurons from treatment-resistant depression and healthy volunteers.

Johnston JN, Jones GH, Peng S +12

Europe PMC2026
ArticleKetamine

Mindfulness, music, visual occlusion in ketamine therapy for depression: do they change outcomes? A qualitative and quantitative analysis of a randomized controlled trial.

Kheirkhah M, McDonald N, Aepfelbacher J +17

Europe PMC2025
ArticleKetamine

Exploring the impact of music on response to ketamine/esketamine: A scoping review.

Kheirkhah M, Nugent AC, Livinski AA +11

Europe PMC2024
ArticleKetamine

Ketamine in neuropsychiatric disorders: an update.

Johnston JN, Kadriu B, Kraus C +2

Europe PMC2024
ArticleKetamine

Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment.

Johnston JN, Kadriu B, Allen J +3

Europe PMC2023
ArticleKetamine

Ketamine and Serotonergic Psychedelics: Common Mechanisms Underlying the Effects of Rapid-Acting Antidepressants.

Kadriu B, Greenwald M, Henter ID +4

Europe PMC2021
ArticleKetamine

The influence of ketamine on drug discovery in depression.

Kraus C, Wasserman D, Henter ID +3

Europe PMC2019